Clinical Genomics
| SR NO | TEST | TEST COMPONENTS | METHOD | SPECIMEN/TRANSPORT | TAT | CLINICAL APPLICATIONS |
|---|---|---|---|---|---|---|
| 1 | Broad Range Bacterial (16SRNA) Identification | A broad range of infectious organisms | Next-Generation Sequencing | Culture colonies preferred/Blood culture/Body fluids | 15 days | identify the rare species in CSF and or sample proceed for culture to identify the bacterial spp. |
| 2 | HBV (Hepatitis B) Analysis-COBAS TAQMAN | Quantitative detection of Hepatitis B viral load by COBAS Taqman | RT-PCR TAQMAN | Plasma, EDTA whole blood (3ml) | 1 day | This test is intended for use as an aid in the management of patients with chronic HBV infection undergoing antiviral therapy. The test can be used to measure HBV DNA levels at baseline and during treatment to aid in assessing response to treatment. The results from this test must be interpreted within the context of all relevant clinical and laboratory finding. |
| 3 | HBV Drug Resistance and Genotyping | Mutation in RT region of HBV | Sanger Sequencing | Plasma, EDTA whole blood (3ml) | 7 days | In patients with confirmed treatment adherence who exhibit virologic breakthrough or rebound, resistance testing can be used to confirm the presence of mutations and therefore guide selection of subsequent therapy. |
| 4 | HBV (Hepatitis B) Genotyping | Genotyping of Hepatitis B virus | Sanger Sequencing | Plasma, EDTA whole blood (3ml) | 4 days | HBV genotypes A–H are classified according to sequence variations in the HBV “S” gene and have distinct geographic distributions. Genotype analysis may have prognostic value. |
| 5 | HBV Basal core/precore mutation analysis | Mutation detection in pre-C and BCP region of HBV | Sanger Sequencing | Plasma, EDTA whole blood (3ml) | 7 days | In patients with confirmed treatment adherence who exhibit virologic breakthrough or rebound, resistance testing can be used to confirm the presence of mutations and therefore guide selection of subsequent therapy. |
| 6 | HCV (Hepatitis C) Qualitative Detection | Qualitative detection of Hepatitis C virus | Real Time PCR | Plasma, EDTA whole blood (3ml) | 1 day | This test is intended for use in conjunction with clinical presentation and other laboratory markers of disease progress for the clinical management of HCV infected patients. |
| 7 | HCV (Hepatitis C) Quantitative Analysis | Quantitative detection of Hepatitis C viral load | Real Time PCR | Plasma, EDTA whole blood (3ml) | 1 day | This test is intended for use in conjunction with clinical presentation and other laboratory markers of disease progress for the clinical management of HCV infected patients. The test can be used to monitor the HCV RNA level during the course of antiretroviral treatment. |
| 8 | HCV (Hepatitis C) Analysis- COBAS TAQMAN | Quantitative detection of Hepatitis C viral load by COBAS Taqman | RT-PCR TAQMAN | Plasma, EDTA whole blood (3ml) | 1 day | This test is intended for use in conjunction with clinical presentation and other laboratory markers of disease progress for the clinical management of HCV infected patients. The test can be used to monitor the HCV RNA level during the course of antiretroviral treatment. |
| 9 | HCV (Hepatitis C) Genotyping | Genotyping of Hepatitis C virus | Sanger Sequencing | Plasma, EDTA whole blood (3ml) | 4 days | Determining hepatitis C virus genotype (1 to 5) to guide antiviral therapy in patients with chronic hepatitis C |
| 10 | HIV-1 (Human Immuno Deficiency) Qualitative Detection | Qualitative detection of Human Immunodeficiency virus type 1 | Real Time PCR | Plasma, EDTA whole blood (3ml) | 1 day | This test is intended for use in conjunction with clinical presentation and other laboratory markers of disease progress for the clinical management of HIV-1 infected patients. The test can be used to assess the baseline HIV-1 RNA level. |
| 11 | HIV-1 Quantitative Analysis | Quantitative detection of Human Immunodeficiency virus type 1 | Real Time PCR | Plasma, EDTA whole blood (3ml) | 1 day | This test is intended for use in conjunction with clinical presentation and other laboratory markers of disease progress for the clinical management of HIV-1 infected patients. The test can be used to monitor the HIV-1 RNA level during the course of antiretroviral treatment. |
| 12 | HIV-1 Analysis- COBAS TAQMAN | Quantitative detection of Human Immunodeficiency virus type 1 by COBAS Taqman | RT-PCR TAQMAN | Plasma, EDTA whole blood (3ml) | 1 day | This test is highly sensitive and intended for use in conjunction with clinical presentation and other laboratory markers of disease progress for the clinical management of HIV-1 infected patients. The test can be used to monitor the HIV-1 RNA level during the course of antiretroviral treatment. |
| 13 | HIV Drug Resistance and Genotyping | Antiretroviral susceptibility information for protease inhibitors (PI) and reverse transcriptase inhibitors (NRTI, NNRTI) | Sanger Sequencing | Plasma, EDTA whole blood (3ml) | 7 days | This test helps in guiding the clinician for targeted therapy in the cases where patients are not responding towards the drugs. |
| 14 | HIV Integrase Inhibitor Drug Resistance | Antiretroviral susceptibility information for integrase inhibitors (INI) | Sanger Sequencing | EDTA whole blood (3ml) | 7 days | This test helps in guiding the clinician for targeted therapy in the cases where patients are not responding towards the drugs. |
| 15 | HIV Drug Resistance and Genotyping, Comprehensive | Antiretroviral susceptibility information for protease inhibitors (PI), reverse transcriptase inhibitors (NRTI, NNRTI) and integrase inhibitors (INI) | Sanger Sequencing | EDTA whole blood (3ml) | 7 days | This test helps in guiding the clinician for targeted therapy in the cases where patients are not responding towards the drugs. |
| 16 | HIV-1 Pro-viral DNA Qualitative detection | Qualitative detection of HIV1 provirus | Real Time PCR | Cervical swab, Tissue Blocks | 1 day | HIV-1 proviral tests are recommended at 14 to 21 days, 1 to 2 months, and 4 to 6 months after birth, in infants born to HIV-1-infected mothers. Breastfeeding infants should be tested at baseline (1 to 2 days), 4 to 6 weeks, 3 months, and 4 to 6 months after birth. Two consecutive positive HIV-1 virologic test results (HIV-1 DNA and/or RNA) are necessary for confirming the diagnosis of HIV-1 infection in infants younger than 18 months of age. |
| 17 | HPV (Human Papilloma Virus) Qualitative Detection | Qualitative detection of Human Papilloma virus (HPV) 16&18 | Real Time PCR | Cervical swab, Tissue Blocks | 7 days | The test is intended to detect high-risk HPV subtypes 16 and 18 to determine potential cancer risk |
| 18 | HPV (Human Papilloma Virus) DNA Detection | Genotyping of HPV 16&18 | Sanger Sequencing | EDTA whole blood (3ml) | 1 day | Detects HPV in the specimen |
| 19 | EBV (Epstein Barr Virus) Qualitative Detection | Qualitative detection of Epstein Barr Virus (EBV) | Real Time PCR | EDTA whole blood (3ml) | 1 day | Epstein-Barr virus (EBV) is the cause of a variety of disorders, including infectious mononucleosis (IM). Laboratory testing can help determine whether someone is susceptible to EBV infection or has a recent or past infection. |
| 20 | EBV (Epstein Barr Virus) Quantitative Analysis | Quantitative detection of Epstein Barr Virus (EBV) | Real Time PCR | EDTA whole blood (3ml) | 1 day | Epstein-Barr virus (EBV) is the cause of a variety of disorders, including infectious mononucleosis (IM). Laboratory testing can help determine whether someone is susceptible to EBV infection or has a recent or past infection. |
| 21 | CMV (Cytomegalo Virus) DNA Qualitative Detection | Qualitative detection of Human Cytomegalovirus (CMV) | Real Time PCR | EDTA whole blood (3ml) | 1 day | CMV infection is of clinical significance primarily in pregnant women, newborn infants with possible congenital infection, immunosuppressed transplant patients and immunocompromised individuals. |
| 22 | CMV (Cytomegalo Virus) DNA Quantitative Analysis | Quantitative detection of Human Cytomegalovirus (CMV) | Real Time PCR | CSF, EDTA whole blood (3ml) | 1 day | CMV infection is of clinical significance primarily in pregnant women, newborn infants with possible congenital infection, immunosuppressed transplant patients and immunocompromised individuals. |
| 23 | HSV (Herpes Simplex Virus) I & II Qualitative Detection | Qualitative detection of Herpes Simplex Virus 1&2 | Real Time PCR | EDTA whole blood (3ml) | 1 day | DNA testing is analytically more sensitive than culture, especially in patients with encephalitis or meningitis. DNA testing may be useful in diagnosis of infection in neonates. Neonates who have been exposed to HSV can develop disseminated infection and encephalitis. Encephalitis is usually due to HSV I whereas meningitis is usually due to HSV II. DNA testing provides reliable means to define the type. |
| 24 | Dengue Qualitative detection | Qualitative detection of Dengue virus | Real Time PCR | EDTA whole blood (3ml) | 1 day | This test is intended to diagnose Dengue fever infection during the initial stage of infection, days 1-5 after onset of symptoms, which is able to detect dengue virus subtypes 1-4. |
| 25 | Chikungunya Qualitative detection | Qualitative detection of Chikungunya virus | Real Time PCR | EDTA whole blood (3ml), Urine, Swab | 1 day | This test is intended to diagnose chikungunya fever infection during the initial stage of infection. |
| 26 | Chlamydia qualitative Detection | Qualitative detection of Chlamydia trachomatis | Real Time PCR | EDTA whole blood (3ml), Urine, Swab | 1 day | This test is used to screen for the infections caused by the bacteria Chlamydia trachomatis. |
| 27 | Neisseria Gonorrhoea Qualitative Detection | Qualitative detection of Neisseria Gonorrhoea | Real Time PCR | EDTA whole blood (3ml) | 1 day | This test is used to screen for the infections caused by the Neisseria gonorrhoea |
| 28 | Rubella Qualitative Detection | Qualitative detection of Rubella virus | Real Time PCR | CSF, EDTA whole blood (3ml) | 1 day | For the rapid diagnosis of congenital rubella virus infection. |
| 29 | Japanese Encephalitis Virus | Qualitative detection of Japanese Encephalitis virus | Real Time PCR | CSF, EDTA whole blood (3ml) | 1 day | This test is intended to identify JEV in the specimen |
| 30 | Parvo Virus B 19 Qualitative Detection | Qualitative detection of Parvo B19 virus | Real Time PCR | CSF, EDTA whole blood (3ml) | 1 day | Diagnose and monitor human parvovirus infection in patient with suppressed or delayed immune response. |
| 31 | Toxoplasma Qualitative Detection | Qualitative detection of Toxoplasma virus | Real Time PCR | EDTA whole blood (3ml) | 1 day | Confirm toxoplasmosis infection in immunocompromised hosts as well as fetuses and newborns. |
| 32 | Varicella Zoster Virus (VZV) Qualitative Detection | Qualitative detection of VZV | Real Time PCR | EDTA whole blood (3ml), AF, CVS | 1 day | This test is intended to identify rapid idenfication of VZV in the specimen |
| 33 | TORCH-PCR qualitative Detection | Qualitative detection of Toxovirus, Rubella virus, CMV, HSV | Real Time PCR | CSF | 1 day | These groups of infections are the main threats of serious congenital infection during pregnancy, which may ultimately cause fetal damage or other anomalies. |
| 34 | Viral Encephalitis Panel Qualitative Detection | Qualitative detection of HSV I&II, VZV, Enterovirus, mumps virus, Human parechovirus | Real Time PCR | CSF | 1 day | This panel may assist in identifying important infectious agents causing encephalitis or meningoencephalitis. |
| 35 | CSF- Viral Panel Qualitative Detection | Qualitative detection of EBV, CMV, VZV, HSVI&II, JC | Real Time PCR | EDTA whole blood (3ml), Urine | 1 day | This panel may assist in identifying important infectious agents causing viral diseases |
| 36 | BK Polyoma Virus Quantitative Detection | Qualitative detection of BK polyoma virus | Real Time PCR | EDTA whole blood (3ml), Urine, CSF | 1 day | The presence of BKV DNA in blood reflects the dynamics of the disease: the conversion of plasma from negative to positive for BKV DNA after transplantation, the presence of DNA in plasma in conjunction with the persistence of nephropathy, and its disappearance from plasma after the reduction of immunosuppressive therapy. However, BKV DNA is typically detectable in urine prior to plasma and may serve as an indication of impending BKV associated nephropathy. |
| 37 | JC Polyoma Virus Quantitative Detection | Qualitative detection of JC polyoma virus | Real Time PCR | EDTA whole blood (3ml), Urine, CSF | 1 day | Detection of JC virus (JCV) DNA supports the clinical diagnosis of progressive multifocal leukoencephalopathy (PML) due to JCV. |
| 38 | Mycobacterium tuberculosis Qualitative Detection | Qualitative detection of MTB | Real Time PCR | EDTA whole blood (3ml), Urine, CSF, Swab, Tissue, FFPE Blocks, Body Fluids | 1 day | This rapid PCR test detects MTB DNA from the specimen. |
| 39 | Zika Virus | Qualitative detection of Zika virus | Real Time PCR | Serum, Urine | 1 day | Provides qualitative detection of Zika virus RNA from urine collected during the acute phase of infection. |
| 40 | Influenza Virus | Qualitative detection of Influenza A, Influenza B, HINI | Real Time PCR | Nasopharyngeal swab | 1 day | Provides qualitative detection of Influenza virus RNA. |
| SR NO | TEST | TEST COMPONENTS | METHOD | SPECIMEN/TRANSPORT | TAT | CLINICAL APPLICATIONS |